Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Pacira Pharmaceuticals, Inc..
Pacira Pharmaceuticals, Inc. is a company.
Key people at Pacira Pharmaceuticals, Inc..
Pacira BioSciences, Inc. (formerly Pacira Pharmaceuticals) is a specialty pharmaceutical company pioneering non-opioid pain management solutions, primarily through its flagship product EXPAREL (bupivacaine liposome injectable suspension), a long-acting local anesthetic providing pain relief for up to 72 hours post-surgery.[1][3][4] It serves surgical specialties like orthopedic, general, and plastic surgery, addressing the opioid crisis by offering alternatives that reduce opioid reliance for millions of patients.[3][4] The company projects $730–750 million in total revenue for fiscal 2025, driven by EXPAREL growth, with an expanding pipeline including gene therapies for osteoarthritis and chronic pain.[1][3]
Pacira solves acute and chronic pain challenges using proprietary pMVL (multivesicular liposome) drug delivery technology for extended-release formulations, alongside innovations like ZILRETTA and in-licensed assets.[1][3] Recent momentum includes accelerated EXPAREL volume growth, improved payer coverage for NOPAIN, a J&J MedTech partnership for ZILRETTA, and pipeline progress like completing Phase 2 enrollment for PCRX-201 (enekinragene inzadenovec) in November 2025.[1][3]
Pacira traces its roots to predecessors DepoTech and SkyePharma, with the company formally founded in 2006 (though some sources cite 1997 as the foundational year for its technology base).[1][2][3] It emerged focused on postsurgical pain management amid rising opioid concerns, leveraging advanced drug delivery systems to create non-opioid alternatives.[1][2][3] Early traction came from developing EXPAREL, which established Pacira as a leader in targeted pain relief, building on over two decades of innovation in the space.[1][4]
Pivotal moments include rebranding to Pacira BioSciences to reflect its evolution into a broader biopharma player, the February 2025 acquisition of GQ Bio Therapeutics for gene therapy platforms, and in-licensing AMT-143 as a long-acting analgesic.[1][3] These steps marked a shift from single-product reliance to a diversified pipeline, humanizing its mission to transform patient lives beyond opioids.[4]
Pacira rides the non-opioid pain management trend, fueled by the U.S. opioid crisis and regulatory pushes for alternatives, transforming surgical care across specialties.[1][3][4] Timing is ideal amid post-pandemic surgery backlogs and payer incentives for opioid-sparing therapies, with EXPAREL's market penetration signaling strong demand.[1][3] Favorable forces include clinical data supporting long-acting locals, gene therapy advancements, and partnerships like J&J's for ZILRETTA, enhancing ecosystem access.[3]
It influences biotech by pioneering drug delivery innovations, inspiring regenerative health shifts, and leading musculoskeletal pain solutions, potentially setting standards for decades via genetic medicines.[1][4]
Pacira's trajectory hinges on pipeline execution, with PCRX-201 Phase 2 data and next-gen assets like AMT-143 poised to diversify beyond EXPAREL amid 2025 revenue strength.[1][3] Trends like gene therapies for osteoarthritis, expanded payer coverage, and manufacturing gains will shape growth, targeting market leadership in non-opioid innovation.[1][3] Influence may evolve through high-risk bets paying off, solidifying its role as a pain management transformative force—echoing its founding mission to redefine relief without opioids.[4]
Key people at Pacira Pharmaceuticals, Inc..
